Any current/future new fundraising through debt or equity?

Eris Lifesciences intends to raise around Rs. 1,250 crores through Non-Convertible Debentures (NCDs). The purpose is to repay Commercial Papers (CPs) due in first or second week of June. The company plans to continue deleveraging, targeting a debt-to-EBITDA ratio of less than 2x by September 2025. They plan to repay Rs. 400 crores of debt via internal accruals in FY25 and Rs. 600 crores in the following year. Capex of Rs. 70-80 crores per year is planned for the next two years, mainly for manufacturing units to insource Biocon Injectables portfolio. No new equity fundraising is explicitly ment

Any current/future capex/capital investment/strategic investment?

Capex of Rs. 70 to 80 crores planned annually for FY25 and FY26. Investments focused on setting up manufacturing units at Ahmedabad for insourcing Biocon products, including Insulins, Oncology, and Hormones. Capacity creation is needed for specialized containment units related to these therapies. Emphasis on converting the Biocon Injectables portfolio in-house. Investment in strengthening the production footprint to support export of oral solid dose forms and leverage Swiss Parenterals' channel. Continued investment in in-house manufacturing sites (Guwahati and Ahmedabad), which currently acco

Future growth expectations in sales/revenue/volumes?

Eris Lifesciences expects organic revenue growth of 12% to 15% in Domestic Branded Formulations for FY25, continuing the momentum seen with 15% organic growth in Q4 FY24. The company is well-positioned for a diversified therapy mix driving this growth, supported by strong Diabetes portfolio including Linagliptin, Dapagliflozin combinations, and Vildagliptin in the generic space. Over 20 first-in-market launches from their own R&D pipeline are anticipated, along with integration benefits from acquisitions like Biocon Injectables and Swiss Parenterals. Expansion of new therapies such as De

Future growth expectations in earnings/operating earnings/profits/EPS?

Eris Lifesciences expects sustained organic revenue growth of 12%–14% in Domestic Branded Formulations for FY25, following a 9%–10% growth in FY24. EBITDA margins for Domestic Formulations are expected to maintain around 36%. Adjusted consolidated EBITDA for FY24 was Rs. 713 crores (36% margin), with adjusted PAT at Rs. 432 crores (22% margin), showing 33% and 16% growth YoY, respectively. Earnings Per Share (EPS) for FY24 was Rs. 29 (6% growth YoY) with cash EPS at Rs. 38 (14% growth). Margin expansion and earnings growth are anticipated as integration and normalization progress, especially i

Current/ Expected Orderbook/ Pending Orders?

No explicit mention of a current or expected order book or pending orders in the provided transcript. Amit Bakshi mentioned new product launches in the pipeline: - Two products launched this fiscal (Feb-Mar): Gliclazide with Sitagliptin combination. - Awaiting approval and additional bioequivalence (BE) study for a third triple drug. - Marketing authorization obtained for Dapagliflozin and Metoprolol; awaiting final licenses. - Next product in line: Dapagliflozin with Bisoprolol, targeting heart failure. - Expected launches mainly in Q1, with quieter Q2 and pickup in Q3. R&D pipel

IN US

Sale is live|00:00:00left today

ERIS Lifesciences LtdQ1 FY24Pharmaceuticals & Biotechnology

ERIS Lifesciences Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,461P/E: 42.8Market Cap: ₹19.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Eris Lifesciences expects organic revenue growth of 12% to 15% in Domestic Branded Formulations for FY25, continuing the momentum seen with 15% organic growth in Q4 FY24.
→The company is well-positioned for a diversified therapy mix driving this growth, supported by strong Diabetes portfolio including Linagliptin, Dapagliflozin combinations, and Vildagliptin in the generic space.
→Over 20 first-in-market launches from their own R&D pipeline are anticipated, along with integration benefits from acquisitions like Biocon Injectables and Swiss Parenterals.
→Expansion of new therapies such as Dermatology, Oncology, Nephrology, Immunology, and Insulins is expected to further contribute to secular growth.
→Manufacturing insourcing and capacity additions (Ahmedabad plant) are planned to support revenue scaling and margin enhancement.
→Growth in large brands and new product launches positions the company to continue outpacing market growth.

Margin guidance

Category 3

→Eris Lifesciences expects sustained organic revenue growth of 12%–14% in Domestic Branded Formulations for FY25, following a 9%–10% growth in FY24.
→EBITDA margins for Domestic Formulations are expected to maintain around 36%.
→Adjusted consolidated EBITDA for FY24 was Rs. 713 crores (36% margin), with adjusted PAT at Rs. 432 crores (22% margin), showing 33% and 16% growth YoY, respectively.
→Earnings Per Share (EPS) for FY24 was Rs. 29 (6% growth YoY) with cash EPS at Rs. 38 (14% growth).
→Margin expansion and earnings growth are anticipated as integration and normalization progress, especially in newer therapies like Dermatology, Oncology, Insulins, and Nephrology.
→Operating cash flow conversion is strong at 70%–75% of EBITDA, supporting debt reduction and margin stability.
→Breakeven achieved for MJ Biopharm; run rate improving, indicating profitability momentum.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Eris Lifesciences intends to raise around Rs. 1,250 crores through Non-Convertible Debentures (NCDs).
→The purpose is to repay Commercial Papers (CPs) due in first or second week of June.
→The company plans to continue deleveraging, targeting a debt-to-EBITDA ratio of less than 2x by September 2025.
→They plan to repay Rs. 400 crores of debt via internal accruals in FY25 and Rs. 600 crores in the following year.
→Capex of Rs. 70-80 crores per year is planned for the next two years, mainly for manufacturing units to insource Biocon Injectables portfolio.
→No new equity fundraising is explicitly mentioned in the disclosed sections.

Order book

→No explicit mention of a current or expected order book or pending orders in the provided transcript.
→Amit Bakshi mentioned new product launches in the pipeline:
→ - Two products launched this fiscal (Feb-Mar): Gliclazide with Sitagliptin combination.
→ - Awaiting approval and additional bioequivalence (BE) study for a third triple drug.
→ - Marketing authorization obtained for Dapagliflozin and Metoprolol; awaiting final licenses.
→ - Next product in line: Dapagliflozin with Bisoprolol, targeting heart failure.
→ - Expected launches mainly in Q1, with quieter Q2 and pickup in Q3.
→R&D pipeline includes over 20 first-in-market launches with good visibility post Q1.
→No direct figures or value of order book mentioned.

Capex plans

Yes

→Capex of Rs. 70 to 80 crores planned annually for FY25 and FY26.
→Investments focused on setting up manufacturing units at Ahmedabad for insourcing Biocon products, including Insulins, Oncology, and Hormones.
→Capacity creation is needed for specialized containment units related to these therapies.
→Emphasis on converting the Biocon Injectables portfolio in-house.
→Investment in strengthening the production footprint to support export of oral solid dose forms and leverage Swiss Parenterals' channel.
→Continued investment in in-house manufacturing sites (Guwahati and Ahmedabad), which currently account for around 60% of Domestic Branded Formulations revenue.
→Strategic investment directed at business integration and new product launches, with over 20 first-in-market launches expected from the R&D pipeline.

How does ERIS Lifesciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1ERIS Lifesciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like ERIS Lifesciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio